FY2025 · ended Dec 31, 2025 · Revenue $1.12M, +2511.6% YoY · Filed Mar 30, 2026
Renovorx, Inc. (RNXT) files with the SEC under industry code 3841, Surgical & Medical Instruments & Apparatus. In fiscal 2025, which ended Dec 31, 2025, it reported revenue of $1.1 million and a net loss of $11.2 million. Free cash flow was -$11.0 million. As of Jun 30, 2026 it held $9.5 million in cash and investments and $390,000 in total debt.
Revenue (TTM)
$1.98M
Net income (TTM)
$-12.29M
-15.2% vs year-ago TTM
Operating cash flow (TTM)
$-11.87M
-15.1% vs year-ago TTM
Free cash flow (TTM)
$-11.94M
EPS (TTM)
$-0.31
+14.4% vs year-ago TTM
Dividend per share
None
Shares outstanding
45.05M
+23.3% vs prior year
Net cash
$9.09M
as of Jun 30, 2026
Operating margin
-685.2%
FY 2026
Company profile
- Industry
- Surgical & Medical Instruments & Apparatus (SIC 3841)
- Listed as
- RNXT (Nasdaq)
- Fiscal year ends
- December 31
- Incorporated in
- DE
- Headquarters
- Mountain View, CA
- SEC filer status
- , Emerging growth company
- SEC CIK
- 1574094
Other Surgical & Medical Instruments & Apparatus companies
- Stryker Corp SYK
- 3M Co MMM
- Boston Scientific Corp BSX
- Becton Dickinson & Co BDX
- Medline Inc. MDLN
- Resmed Inc RMD
- Dexcom Inc DXCM
- Fresenius SE & Co. KGaA FSNUY
All 151 Surgical & Medical Instruments & Apparatus companies
Key figures
Fiscal-year totals from the annual reports. Balance sheet lines are as of each year end.
| Line | FY 2025 Dec 31, 2025 |
FY 2024 Dec 31, 2024 |
FY 2023 Dec 31, 2023 |
FY 2022 Dec 31, 2022 |
FY 2021 Dec 31, 2021 |
|---|---|---|---|---|---|
| Revenue | $1.1M | $43,000 | — | — | — |
| Operating income | -$12.5M | -$11.0M | -$11.4M | -$9.9M | -$5.7M |
| Net income | -$11.2M | -$8.8M | -$10.2M | -$9.9M | -$6.3M |
| Diluted EPS | -$0.32 | -$0.40 | -$0.99 | — | — |
| Operating cash flow | -$11.0M | -$9.1M | -$10.3M | -$8.8M | -$5.9M |
| Free cash flow | -$11.0M | -$9.1M | — | — | — |
| Total assets | $8.1M | $8.1M | $1.5M | $7.3M | $16.3M |
| Total liabilities | $2.7M | $3.6M | $4.5M | $1.1M | $938,000 |
| Stockholders' equity | $5.4M | $4.5M | $3.0M | $6.2M | $15.3M |
| Cash and investments | $7.0M | $7.2M | $1.2M | $6.4M | $15.2M |
| Total debt | $212,000 | $278,000 | — | — | $30,000 |
Recent SEC filings
| Form | Description | Filed | Period |
|---|---|---|---|
| 8-K |
Current report
Other events
|
Aug 20, 2026 | Aug 20, 2026 |
| 10-Q | Quarterly report | Aug 13, 2026 | Jun 30, 2026 |
| 8-K/A |
Amended current report
Results of operations
|
Aug 13, 2026 | Aug 12, 2026 |
| 8-K | Current report | Aug 12, 2026 | Aug 12, 2026 |
| 8-K |
Current report
Other events
|
Aug 4, 2026 | Aug 4, 2026 |
| 8-K |
Current report
Listing notice
|
Jul 2, 2026 | Jul 1, 2026 |
All 290 Renovorx, Inc. SEC filings
Source: SEC EDGAR filings. This is company-reported data, not investment advice.